标题
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
作者
关键词
-
出版物
Journal of Crohns & Colitis
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2020-07-10
DOI
10.1093/ecco-jcc/jjaa145
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- DOP43 Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders
- (2019) D T Rubin et al. Journal of Crohns & Colitis
- Real-World Experience with Tofacitinib in IBD at a Tertiary Center
- (2019) Roni Weisshof et al. DIGESTIVE DISEASES AND SCIENCES
- Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa
- (2019) Julián Panés et al. Gastroenterologia y Hepatologia
- Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
- (2019) William J. Sandborn et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
- (2019) Bruce E. Sands et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
- (2019) Loriane Lair-Mehiri et al. DIGESTIVE AND LIVER DISEASE
- Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice
- (2019) Javier P Gisbert et al. Journal of Crohns & Colitis
- Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data
- (2019) Fumi Varyani et al. Drug Design Development and Therapy
- Acute severe ulcerative colitis: State of the art treatment
- (2018) Javier P. Gisbert et al. BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
- (2018) Stephen Hanauer et al. Clinical Gastroenterology and Hepatology
- Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
- (2018) María Chaparro et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
- (2018) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
- (2017) Marcus Harbord et al. Journal of Crohns & Colitis
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation
- (2016) Carlos Taxonera et al. DIGESTIVE DISEASES AND SCIENCES
- Maintenance therapy options for ulcerative colitis
- (2016) María Chaparro et al. EXPERT OPINION ON PHARMACOTHERAPY
- Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response
- (2012) Lior Katz et al. INFLAMMATORY BOWEL DISEASES
- Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term durability of response to adalimumab in Crohnʼs disease
- (2011) M. Chaparro et al. INFLAMMATORY BOWEL DISEASES
- Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response
- (2011) María Chaparro et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis
- (2008) James D. Lewis et al. INFLAMMATORY BOWEL DISEASES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More